• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb Company BMY 3 Star

Last Price$51.18Day Change (%)-1.02%
Open Price$51.69Day Change ($)-0.53
Day Range51.14–51.9652-Week Range45.70–57.49

As of Tue 09/30/2014 06:32 PM EST | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer

    European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer

  2. Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 ...

    Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

  3. Research and Markets: Global Antibiotics Market 2014-2018: AstraZeneca, Eli Lilly, GSK, Johnson & Johnson, Novartis, Pfizer & Sanofi Lead the Market

    Research and Markets: Global Antibiotics Market 2014-2018: AstraZeneca, Eli Lilly, GSK, Johnson & Johnson, Novartis, Pfizer & Sanofi Lead the Market

  4. Research and Markets: PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

    Research and Markets: PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  5. Corporate Social Responsibility Weekly Recap (September 17, 2014 – September 24, 2014)

    Corporate Social Responsibility Weekly Recap (September 17, 2014 – September 24, 2014)

  6. InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action

    InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action

  7. CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors

    CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors

  8. BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi

    BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.